Posted inCardiology news
TAVR vs. Surgery in Low-Risk Patients: 7-Year PARTNER 3 Results Confirm Long-Term Parity
Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alternative to surgery in this population.